학술논문
Protocol for the EACH trial: A multicentre phase II study evaluating the safety and antitumour activity of the combination of avelumab, an anti-PD-L1 agent, and cetuximab, as any line treatment for patients with recurrent/metastatic head and neck squamous cell cancer (HNSCC) in the UK
Document Type
Article
Author
Source
In: BMJ Open . (BMJ Open, 27 November 2023, 13(11))
Subject
Language
English
ISSN
20446055